Praxis Precision Medicines, Inc. Common Stock
PRAXPraxis Precision Medicines, Inc. (PRAX) is a biotechnology company focused on developing targeted therapies for neuroscience and rare diseases. The company leverages precision medicine approaches to create treatments tailored to specific genetic and molecular profiles, aiming to improve outcomes for patients with neurological and neuropsychiatric conditions.
Company News
Praxis Precision Medicines reported positive results from its EMBOLD study for SCN2A and SCN8A developmental and epileptic encephalopathies, leading to a significant stock price increase and potential FDA review.
Praxis Precision Medicines plans to raise approximately $525 million through a public offering of 3,025,480 common stock shares and pre-funded warrants at $157.00 per share, with underwriters including TD Cowen, Piper Sandler, Guggenheim Securities, and Truist Securities.
Praxis Precision Medicines reported a wider Q2 2025 loss of ($3.31) per share, with no revenue and doubled research expenses. The company continues advancing clinical trials for neurological disorder treatments, with promising results in epilepsy drug vormatrigine and receiving Breakthrough Therapy Designation for relutrigine.
JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on suvecaltamide.
What the latest PPI inflation data signals for inflation & the stock market today. The post PPI Report Live: Producer Price Inflation Report Is Out, Here’s What It Shows appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
